August 2015 - Cancer Currents Blog
- Overdiagnosis of Cancer: Bringing an Important Problem into Focus
Experts are convening for a conference on the dilemmas posed by overdiagnosis in many types of diseases. Overdiagnosis is generally defined as the diagnosis of a disease or condition that is unlikely to ever cause harm.
- Risk of Breast Cancer Death is Low After a Diagnosis of Ductal Carcinoma in Situ
Women who are diagnosed with a condition called ductal carcinoma in situ generally have a low risk of dying from breast cancer, a new study has found.
- FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple Myeloma
The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
- With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung Cancer
The FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.
- Gene Therapy Approach for Ovarian Cancer Shows Encouraging Signs in Animal Model
A single injection of a gene therapy viral vector inhibited tumor growth of some mouse tumors derived from patients with recurrent ovarian cancer.
- Too Few Patients with Cancer Communicate Preferences for End-of-Life Care
Many patients with cancer and their physicians are not communicating about the patients’ preferences for end-of-life medical care, a new study suggests.
- NCI-Designated Cancer Centers Expand, Four Awarded Comprehensive Designation
In July 2015, the NCI’s cancer centers program expanded by adding a new institution and awarding the comprehensive designation to four existing NCI-designated cancer centers.